News Regeneron forges CAR-T R&D partnership with bluebird bio Deal combines Regeneron's receptor tech with CAR-T biotech's expertise
News Spectacular results for bluebird's gene therapy in thalassem... Patients with the rare blood disorders transfusion-dependent β-thalassemia (TDT) have shown spectacular results in clinical trials of bluebird bio's gene therapy, raising hopes the treatmen
News Scotland's TC BioPharm joins bluebird to develop next-gen CA... US cancer biotech bluebird bio has joined with TC BioPharm in a collaboration focused on gamma delta CAR-T cells.
News More good news for Bluebird Bio with CALD gene therapy Bluebird Bio has presented encouraging data from its gene therapy treatment for t
News Roche places a $1bn bet on C4T degrader-antibody conjugates Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
